Artemisia annua Leaf Extract Attenuates Hepatic Steatosis and Inflammation in High-Fat Diet-Fed Mice

Journal of Medicinal Food

Volumn 19, Issue 3, 2016, Pages 290-299

  Kim, Kyung Eun ^a   Ko, Keon Hee ^b,c   Heo, Rok Won ^a   Yi, Chin Ok ^a   Shin, Hyun Joo ^a   Kim, Jun Young ^d   Park, Jae Ho ^e   Nam, Sanghae ^c   Kim, Hwajin ^a   Roh, Gu Seob ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Sancheong Oriental Medicinal Herb Institute   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Korea Food and Drug Administration   (South Korea)

^e Shinseon FandV Co   (South Korea)

Author keywords

Artemisia annua L.; hepatic inflammation; hepatic steatosis; obesity

Indexed keywords

ARTEMISIA ANNUA EXTRACT; CARBOHYDRATE BINDING PROTEIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; HIGH MOBILITY GROUP PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSFORMING GROWTH FACTOR; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; FIBROGENESIS; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPOGENESIS; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; ARTEMISIA ANNUA; C57BL MOUSE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; PLANT LEAF;

ANIMALS; ARTEMISIA ANNUA; CYCLOOXYGENASE 2; DIET, HIGH-FAT; FATTY LIVER; HUMANS; MALE; MICE; MICE, INBRED C57BL; OBESITY; PLANT EXTRACTS; PLANT LEAVES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84962620582     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.3527     Document Type: Article

References (35)

1. Räth K, Taxis K, Walz G, Gleiter CH, Li SM, Heide L: Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L. (annual wormwood). Am J Trop Med Hyg 2004;70:128-132.
2. Ho WE, Peh HY, Chan TK, Wong WS: Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol Ther 2014;142:126-139.
3. Kim MH, Seo JY, Liu KH, Kim JS: Protective effect of Artemisia annua L. extract against galactose-induced oxidative stress in mice. PLoS One 2014;9:e101486.
4. Zheng GQ: Cytotoxic terpenoids and flavonoids from Artemisia annua. Planta Med 1994;60:54-57.
5. Sun B, Karin M: Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704-713.
6. Postic C, Girard J: The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008;34:643-648.
7. Abelmalek MF, Diehl AM: Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91: 1125-1149.
8. Tu K, Zheng X, Yin G, Zan X, Yao Y, Liu Q: Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Mol Med Rep 2012;6: 525-530.
9. Dentin R, Girard J, Postic C: Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): Two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005;87:81-86.
10. Filhoulaud G, Guilmeau S, Dentin R, Girard J, Postic C: Novel insights into ChREBP regulation and function. Trends Endocrinol Metab 2013;24:257-268.
11. Foufelle F, Ferré P: New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: A role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002;366:377-391.
12. Kamari Y, Shaish A, Vax E, et al.: Lack of interleukin-1a or interleukin-1b inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 2011;55:1086-1094.
13. Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D: Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 2013;19:357-366.
14. Chiang DJ, Pritchard MT, Nagy LE: Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 300:G697-G702.
15. Matsui T, Ueda T, Oki T, Sugita K, Terahara N, Matsumoto K: a-Glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity. J Agric Food Chem 2001;49:1948-1951.
16. Jeon BT, Heo RW, Shin HJ, et al.: Attenuation by a Vigna nakashimae extract of nonalcoholic fatty liver disease in high-fat diet-fed mice. Biosci Biotechnol Biochem 2014;78:482-489.
17. Alexei L, Eba A, Benhilda NM, et al.: Integrating medicinal plants extraction into a high-value biorefinery: An example of Artemisia annua L. C R Chim 2014;17:232-241.
18. Choi HN, Kang MJ, Lee SJ, Kim JI: Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, highsucrose diet. Nutr Res Pract 2014;8:544-549.
19. Huang GJ, Hsieh WT, Chang HY, Huang SS, Lin YC, Kuo YH: a-Glucosidase and aldose reductase inhibitory activities from the fruiting body of Phellinus merrillii. J Agric Food Chem 2011;59: 5702-5706.
20. Kumar S, Narwal S, Kumar V, Prakash O: a-Glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacogn Rev 2011;5:19-29.
21. Willcox ML, Burton S, Oyweka R, Namyalo R, Challand S, Lindsey K: Evaluation and pharmacovigilance of projects promoting cultivation and local use of Artemisia annua for malaria. Malar J 2011;10:84.
22. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119.
23. Liu IM, Tzeng TF, Liou SS, Lan TW: Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abelmoschus moschatus. Planta Med 2007;73:1054-1060.
24. Chang CJ, Tzeng TF, Liou SS, Chang YS, Liu IM: Myricetin increases hepatic peroxisome proliferator-activated receptor a protein expression and decreases plasma lipids and adiposity in rats. Evid Based Complement Alternat Med 2012;2012:787152.
25. Sakurai M, Takamura T, Ota T, et al.: Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J. Gastroenterol 2007;42:312-317.
26. Ferré P, Foufelle F: Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010;12:83-92.
27. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K: Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 2004;101:7281-7286.
28. Tsatsos NG, Davies MN, O'Callaghan BL, Towle HC: Identification and function of phosphorylation in the glucose-regulated transcription factor ChREBP. Biochem J 2008;411:261-270.
29. Dentin R, Benhamed F, Hainaylt, et al.: Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006;55:2159-2170.
30. Iizuka K, Miller B, Uyeda K: Deficiency of carbohydrateactivated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab 2006;291:E358-E364.
31. Benhamed F, Denechaud PD, Lemoine M, et al.: The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 2012;122: 2176-2194.
32. Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW: Inhibition of highmobility group box 1 expression by siRNA in rat hepatic stellate cells. World J. Gastroenterol 2011;17:4090-4098.
33. Chen J, Liu D, Bai Q, et al.: Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats. Mol Med Rep 2011;4:811-816.
34. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC: COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring) 2009; 17:1150-1157.
35. Lipson KE, Wong C, Teng Y, Spong S: CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012; 5:S24.